DGAP-News: Stellar Biotechnologies Listed on Frankfurt Stock Exchange
(firmenpresse) - DGAP-News: Stellar Biotechnologies, Inc. / Key word(s): IPO
Stellar Biotechnologies Listed on Frankfurt Stock Exchange
28.02.2012 / 12:15
---------------------------------------------------------------------
Stellar Biotechnologies Listed on Frankfurt Stock Exchange
PORT HUENEME, CA USA--(February 28, 2012)- Stellar Biotechnologies, Inc.
('Stellar') (TSX-V: KLH.V - News) (Pinksheets: SBOTF.PK - News) (FSE:
RBT.F) is pleased to announce that it has recently listed on the Frankfurt
Stock Exchange (FSE), and will trade under the symbol RBT.F (WKN A1C5EH).
Stellar is the world leader in sustainable manufacturing of pharmaceutical
grade KLH (Keyhole Limpet Hemocyanin).
'We are pleased to be listed on the Frankfurt Stock Exchange,' said Mr.
Frank Oakes, President and CEO of Stellar Biotechnologies. 'As a
forward-thinking company, we are among an increasing number of U.S.
companies focused on expanding our reach in Europe. This new listing will
benefit both Stellar and our shareholders alike as we look to broaden our
shareholder base and awareness in Germany and Europe.'
KLH is sourced from a limited natural resource, and Stellar is the only
company in the world that has turned this limited natural resource into a
renewable one, Mr. Darrell Brookstein, EVP of Corporate Development&Finance said, 'As new applications are developed and demand for
pharmaceutical grade KLH increases, only Stellar is in a position to meet
demand.' Brookstein added, 'I believe the cross-border listing increases
liquidity options and creates new strategic partnership opportunities for
Stellar.'
About Stellar
Stellar Biotechnologies, Inc. (TSX-V: KLH.V - News) (Pinksheets: SBOTF.PK -
News) (FSE: RBT.F) (www.StellarBiotechnologies.com) is the world leader in
sustainable manufacturing of pharmaceutical grade KLH (Keyhole Limpet
Hemocyanin). This evolutionary protein has a highly complex structure that
makes it ideal for use in human and animal vaccines and diagnostic
products. With partners and customers, its flagship Stellar KLH products
are in the clinic, and on the way to being established as the only
sustainable, long-term pharmaceutical source. Stellar Biotechnologies was
founded to address the growing demand for renewable, commercial-scale
supplies of high-quality, GMP-grade KLH. Stellar has developed leading
practices, facilities and proprietary capabilities to address this need. To
receive regular updates, enter email at bottom
ofhttp://stellarbiotechnologies.com/investors/news_releases/.
Stellar Contact:
Contact for Stellar Biotechnologies, Inc.
Darrell Brookstein
Executive VP, Corporate Development&Finance
dbrookstein(at)stellarbiotech.com
Contacts for IR/PR
TheBiotechPanel, Inc.:
Frank Rothmaier - English&German
Managing Director
f.rothmaier(at)thebiotechpanel.com
Ray Campos - English&Spanish
Director
r.campos(at)thebiotechpanel.com
There can be no assurance that forward-looking statements will prove to be
accurate, as actual results and future events could differ materially from
those anticipated in such statements. Readers should not place undue
reliance on such statements. Except in accordance with applicable
securities laws, the Company expressly disclaims any obligation to update
any forward-looking statements or forward-looking statements that are
incorporated by reference herein. This news release does not constitute an
offer tosell, or a solicitation of an offer to buy any of the Company's
securities set out herein in the United States, or to, or for the benefit
or account of, a U.S. Person or person in the United States. Neither TSX
Venture Exchange nor its Regulation Services Provider accepts
responsibility for the adequacy or accuracy of these releases.
End of Corporate News
---------------------------------------------------------------------
28.02.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
158372 28.02.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.02.2012 - 12:15 Uhr
Sprache: Deutsch
News-ID 119247
Anzahl Zeichen: 12506
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 252 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Stellar Biotechnologies Listed on Frankfurt Stock Exchange"
steht unter der journalistisch-redaktionellen Verantwortung von
Stellar Biotechnologies, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
